Association between Mitofusin 2 Gene Polymorphisms and Late-Onset Alzheimer's Disease in the Korean Population
- Authors
- Kim, Young Jong; Park, Jin Kyung; Kang, Won Sub; Kim, Su Kang; Han, Changsu; Na, Hae Ri; Park, Hae Jeong; Kim, Jong Woo; Kim, Young Youl; Park, Moon Ho; Paik, Jong-Woo
- Issue Date
- 1월-2017
- Publisher
- KOREAN NEUROPSYCHIATRIC ASSOC
- Keywords
- MFN2; Mitochondrial fusion; Alzheimer' s disease
- Citation
- PSYCHIATRY INVESTIGATION, v.14, no.1, pp.81 - 85
- Indexed
- SCIE
SSCI
SCOPUS
KCI
- Journal Title
- PSYCHIATRY INVESTIGATION
- Volume
- 14
- Number
- 1
- Start Page
- 81
- End Page
- 85
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/85113
- DOI
- 10.4306/pi.2017.14.1.81
- ISSN
- 1738-3684
- Abstract
- Objective Mitochondrial dysfunction is a prominent and early feature of Alzheimer's disease (AD). The morphologic changes observed in the AD brain could be caused by a failure of mitochondrial fusion mechanisms. The aim of this study was to investigate whether genetic polymorphisms of two genes involved in mitochondrial fusion mechanisms, optic atrophy 1 (OPAL) and mitofusin 2 (MFN2), were associated with AD in the Korean population by analyzing genotypes and allele frequencies. Methods One coding single nucleotide polymorphism (SNP) in the MFN2, rs1042837, and two coding SNPs in the OPAL, rs7624750 and rs9851685, were compared between 165 patients with AD (83 men and 82 women, mean age 72.3 4.41) and 186 healthy control subjects (82 men and 104 women, mean age 76.5 5.98). Results Among these three SNPs, rs1042837 showed statistically significant differences in allele frequency, and genotype frequency in the co-dominant 1 model and in the dominant model. Conclusion These results suggest that the rs1042837 polymorphism in MFN2 may be involved in the pathogenesis of AD.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medical Science > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.